Equities

Vericel Corp

Vericel Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.47
  • Today's Change0.03 / 0.14%
  • Shares traded80.23k
  • 1 Year change-46.58%
  • Beta1.9469
Data delayed at least 15 minutes, as of Nov 25 2022 18:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Vericel Corporation is a commercial-stage biopharmaceutical company. The Company is focused on therapies for the sports medicine and severe burn care markets. It markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

  • Revenue in USD (TTM)159.26m
  • Net income in USD-18.10m
  • Incorporated1989
  • Employees281.00
  • Location
    Vericel Corp64 Sidney StCAMBRIDGE 02139-4170United StatesUSA
  • Phone+1 (734) 930-5555
  • Fax+1 (734) 665-0485
  • Websitehttps://vcel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Northwest Biotherapeutics Inc1.09m56.59m942.30m20.0013.31--16.36867.680.06720.06720.0011-0.09050.0366----54,300.00190.79-293.58--------5,210.50-8,809.02---------22.1510.04133.81--4.02--
Arcellx Inc0.00-170.36m949.00m78.00--4.02-----4.15-4.150.005.390.00----0.00-70.65---80.31--------------0.1882-------102.43------
Pliant Therapeutics Inc9.72m-112.79m960.56m91.00--2.85--98.83-2.93-2.930.25066.910.0318--6.29106,802.20-36.90---39.42-------1,160.53------0.0472---81.89---134.18------
Crinetics Pharmaceuticals Inc5.11m-149.72m973.43m143.00--2.77--190.64-2.99-2.990.10256.530.0172--3.0235,706.29-50.05-39.28-53.37-41.47-----2,912.48-3,934.66----0.00--1,418.3112.85-45.83--18.07--
Iovance Biotherapeutics Inc0.00-389.90m975.45m319.00--2.48-----2.48-2.480.002.490.00----0.00-56.72-45.64-63.36-49.30------------0.0025-------31.85--89.91--
Regenxbio Inc480.03m73.64m978.87m372.0024.401.7411.512.040.92660.926610.7913.020.57--12.221,290,414.008.74-1.9810.13-2.1786.5087.9515.34-5.78--5.050.00--204.30152.43214.91--59.52--
Replimune Group Inc0.00-146.73m994.29m206.00--2.59-----2.74-2.740.007.720.00----0.00-31.23-24.39-32.63-25.47-----------268.420.0652-------45.96--57.90--
Vericel Corp159.26m-18.10m1.01bn281.00--5.70--6.37-0.3837-0.38373.393.770.67463.605.04566,768.70-7.67-5.85-8.49-6.7466.2965.61-11.36-7.185.54--0.0002--25.7723.49-360.86--41.10--
Kura Oncology Inc0.00-135.47m1.01bn127.00--2.37-----2.03-2.030.006.270.00----0.00-26.85-25.80-28.15-27.27------------0.00-------45.57------
USANA Health Sciences, Inc.1.04bn76.88m1.02bn1.98k13.372.4711.260.97923.963.9653.4721.411.832.44--524,742.2013.5520.3418.0627.8680.7382.307.419.982.18--0.000.004.573.35-6.543.09-17.15--
Lyell Immunopharma Inc39.12m-258.43m1.04bn219.00--1.26--26.51-1.04-1.040.1583.290.036----178,625.60-23.76---25.03-------660.62------0.00--37.31---22.37------
Morphic Holding Inc74.23m-56.07m1.06bn101.00--2.90--14.29-1.53-1.531.959.470.1794--45.26734,940.60-13.55---14.61-------75.53------0.00---55.96---112.32------
Deciphera Pharmaceuticals Inc121.89m-221.39m1.08bn280.00--2.87--8.83-3.46-3.461.825.540.25410.45815.90435,321.40-46.15-44.91-54.79-50.3195.04---181.63-556.775.32--0.00--128.45---12.56--92.99--
Biohaven Ltd-100.00bn-100.00bn1.08bn-------------------------------------------------------80.16------
Arcutis Biotherapeutics Inc725.00k-310.77m1.09bn147.00--4.04--1,510.17-5.89-5.890.01394.450.0016--0.51924,931.97-69.37---74.01--62.90---42,864.14--13.27-34.850.4208-------52.09------
Data as of Nov 25 2022. Currency figures normalised to Vericel Corp's reporting currency: US Dollar USD

Institutional shareholders

66.65%Per cent of shares held by top holders
HolderShares% Held
Brown Capital Management LLCas of 30 Sep 20227.41m15.71%
BlackRock Fund Advisorsas of 30 Sep 20226.73m14.26%
The Vanguard Group, Inc.as of 30 Sep 20223.12m6.61%
RTW Investments LPas of 30 Sep 20223.10m6.57%
SSgA Funds Management, Inc.as of 30 Sep 20223.09m6.55%
Fred Alger Management LLCas of 30 Sep 20221.94m4.12%
Ivy Investment Management Co.as of 30 Sep 20221.71m3.62%
Conestoga Capital Advisors LLCas of 30 Sep 20221.53m3.24%
Fisher Asset Management LLCas of 30 Sep 20221.42m3.01%
Morgan Stanley & Co. LLCas of 30 Sep 20221.39m2.95%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.